-
-
Products offered on a not-for-profit basis to the 45 lower-income countries now include the full portfolio for which Pfizer has global rights.
-
Expands on the initial offering of all patented medicines and vaccines available in the U.S. or EU to now include off-patent medicines, bringing total offering from 23 to around 500 products.
-
Builds on already delivered medicines and vaccines along with medical training and supply chain support to Rwanda and advanced conversations with 16 other Accord country governments for supply and health system support.
-
VirtualHealth will receive computing credits and technical expertise from Amazon Web Services for cloud solutions designed to reduce healthcare disparities and advance health equity
-
Analysis of randomized controlled trial data shows non-Caucasian high-risk PCI patients significantly benefit from Impella-support
-
Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced publication of its 2021 Sustainability Review to coincide with the fourth anniversary of the company’s public listing on NASDAQ. “Our company was founded to transform the legacy of an industry through a unique commitment to women’s health and wellbeing. On the fourth anniversary of our listing
-
STALICLA will be a leading contributor to the Euro-Global Platform for Mechanism-based Drug Repurposing (REPO4EU) consortium, with a EUR 1.7 million budget allocated to STALICLA Discovery and Data Science (DDS) unit
-
The virtual healthcare platform and Ukrainian humanitarian non-profit will focus on urgent care needs, prescription renewals, and ordering lab tests for thousands of refugees in the U.S.
-
-
Pfizer will provide all its current and future patent-protected medicines and vaccines available in the U.S. or EU on a not-for-profit basis to 45 lower-income countries.
-
Rwanda, Ghana, Malawi, Senegal and Uganda are the first five countries to commit to join the Accord. Health officials in these countries will help identify and resolve hurdles beyond supply to inform the roll out in all 45 lower-income countries.
-
Pfizer calls upon global health leaders and organizations to join the Accord, bringing their expertise and resources to close the health equity gap and help create a healthier world for 1.2 billion people.
-
Clinical data clear major test for the first precision neurodevelopmental disorders discovery platform, with a first application in Autism Spectrum Disorder (ASD)
-
In partnership with The Geneva Foundation and supporting grant from the Quebec Ministry of Economy and Innovation, Emovi will launch the 24-month clinical project within US Army clinics at Fort Bragg and High Point University, North Carolina, USA
-
Castor named to the 2021 CB Insights Digital Health 150 -- List of Most Innovative Digital Health Startups
-
Strategic partnership to focus on improving maternal outcomes
-
Greenwich LifeSciences to Partner with Susan G. Komen Race for the Cure Houston
-
-
Expanded agreement brings the total number of COVID-19 vaccine doses to be supplied to the U.S. government for donation to one billion
-
Effort contributes to companies’ pledge to deliver two billion COVID-19 vaccine doses to low- and middle-income countries by the end of 2022
-
Alkermes plc (Nasdaq: ALKS) recently announced plans to present clinical data and outcomes research from its psychiatry portfolio at three scientific conferences during Mental Health Awareness Month in May.
-
SOURCE: Novartis SUMMARY:Project brings together Novartis drug discovery and gene therapy expertise and funding support from the Gates Foundation Agreement aims to address disparity in access to treatments and to prioritize populations and regions that bear the greatest burden of sickle cell disease in the search for curative therapies Effort expands on Novartis commitment to sickle cell disease, which includes a therapeutic pipeline and a holistic approach to diagnosis, treatment, and managemen
-
SOURCE: Gilead Sciences DESCRIPTION:After receiving the green light from the FDA to move forward, Gilead is about to start trials of an inhaled version of remdesivir. We will screen healthy volunteers for Phase 1 trials this week and hope to begin studies in patients with COVID-19 in August. If the trials are successful, this could represent important progress. Remdesivir, our investigational antiviral medicine, is currently given to patients intravenously through daily infusions in the hospital.
-
-
Building on Pfizer’s longstanding commitment to fight infectious diseases, grants will help address urgent needs of U.S. and global partners on the front lines of the pandemic
-
Donations complement Pfizer’s COVID-19 R&D investments, as well as collective scientific and philanthropic contributions made by the biopharmaceutical industry
-
U.S. Patient Assistance Program and other programs respond to changing needs of patients and medical community
-
Three leading biopharmaceutical companies have announced programs enabling employees with medical and laboratory expertise to volunteer their services to local healthcare systems and those hardest hit by COVID-19.
-
Collaboration to address product development and scale up challenges posed by current pandemic SOURCE: Novartis DESCRIPTION:BASEL, Switzerland, March 26, 2020/3BL Media/ - Today, Novartis and a consortium of life sciences companies announced an important collaboration to accelerate the development, manufacture and delivery of vaccines, diagnostics, and treatments for COVID-19 in response to the pandemic. The industry brings a range of assets, resources, and expertise needed to identify effective
-
In urgent response to Wuhan Huoshenshan Hospital's request for more accurate, rapid and comprehensive diagnostic platform, Genetron Holdings Limited (“Genetron Health”), a China-based precision oncology company that covers full-cycle cancer care, has announced its donation of GENETRON S5 (China National Medical Device Registration 20193220820) semiconductor high-throughput sequencer and supporting instruments to the hospital. All equipment has arrived at the hospital and went into immediate use.
-
MiraMed Global Services, Inc. (MiraMed), a leader in healthcare revenue cycle management (RCM) services and business process outsourcing (BPO) solutions, is pleased to announce that its recent Circle of Warmth campaign raised $75,000+ dollars for those in need this winter. This money is being used to source the durable EMPWR Coat from the Empowerment Plan that can transform into a sleeping bag at night or an over-the-shoulder bag when not in use. This press release features multimedia. View the
-
“REKOOP” is the first Bedding solution to use Applied DNA’s CertainT
Platform and Reliance Industries’ Recron GreenGold fiber for source
verification and traceability of recycled polyester across the supply
chain; Arrives in US Q1 2019
-
New Partnership to Kick-Off International Expansion